Short answer
Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on July 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Alnylam announced financial results for the quarter ended June 30, 2026.
Alnylam Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Alnylam announced financial results for the quarter ended June 30, 2026
- Detailed operating results and management commentary contained in Exhibit 99.1
- Results provide the latest quarterly update on Alnylam’s financial performance and business trajectory
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.291B, up 67%, with GAAP net income $164.5M versus a $72.2M loss
- AMVUTTRA revenue $1.012B, up 106%, driving total TTR revenue $1.030B, up 89%
- TTR guidance reduced to $4.2B-$4.5B from $4.4B-$4.7B, reflecting normalized U.S. second-line ATTR-CM demand
- Total net product revenue guidance lowered to $4.7B-$5.1B, while collaboration and royalty guidance increased to $575M-$625M
- Cash, cash equivalents and marketable securities reached $3.3B, supporting continued commercial investment and pipeline expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alnylam Pharmaceuticals 8-K filings
Get the next ALNY 8-K as it lands
Follow ALNY for push alerts, or ask the research agent what this filing means.